Latest News

Lilly-Backed Volastra Enters Clinic with Amgen’s KIF18A Inhibitor

  • BioSpace

Volastra licenses Amgen molecule for chromosomally unstable cancers

  • C&EN

Armed with $60M series A and Lilly’s backing, Volastra enters clinic via Amgen cancer med

  • Fierce Biotech

Oncology specialist Volastra brings in PhI drug from Amgen, nabs $60M in Series A

  • Endpoints News

On heels of landmark approval, Bristol Myers Squibb embarks on billion-dollar oncology deal with metastatic cancer startup

  • Endpoints News

Bristol Myers lands $1.1B biobucks oncology pact with Volastra, a biotech with phones ‘ringing off the hook’

  • Fierce Biotech

Volastra, Microsoft team up to battle cancer

  • Wall Street Journal

With fresh investor cash in hand, Volastra partners with Microsoft to develop metastatic cancer biomarker platform

  • Endpoints News